Gabify is India’s first AI-powered SaaS and discovery platform that bridges the gap between families and professionals for the early detection, diagnosis, and therapy support of speech and neurodevelopmental disorders such as Autism, ADHD, Dyslexia, and more.
At its core, Gabify offers two flagship solutions:
NeuroLens by Gabify – An AI-driven, device-agnostic screening tool that identifies risk signs in just minutes. It supports multiple Indian languages, works in low-bandwidth regions, and costs a fraction of traditional assessments. NeuroLens uses voice and facial emotion recognition to screen across multiple disorders simultaneously, making early intervention accessible to all.
Connect by Gabify – A SaaS platform for therapists, parents, and institutions that automates session tracking, documentation, and therapy planning while providing progress dashboards, milestone tracking, and AI-generated child reports. Connect reduces administrative workload for professionals by up to 60% and creates seamless engagement with families.
Gabify’s ecosystem integrates screening, verified expert access, therapy management, and emotional support communities into one unified platform. Recognized by UNDP, TiE, and SISF, and tested across schools and daycare centers, Gabify is on track to impact 1 million children by 2028.
Our vision is simple yet powerful: turn late detection into early empowerment, confusion into clarity, and silence into stories.
Startup Description
Gabify is a healthtech startup on a mission to ensure no child is left behind in their developmental journey. We are building India’s first AI-powered SaaS and discovery platform to transform how families and professionals detect, diagnose, and support children with speech and neurodevelopmental disorders like Autism, ADHD, and Dyslexia.
The problem today is clear: delayed diagnosis, long wait times, high screening costs, and limited accessibility — especially in rural regions. Parents often spend months waiting for assessments that cost up to ₹5,000, only to leave with uncertainty and no clear path forward.
Gabify solves this with two flagship products:
NeuroLens by Gabify – an AI-based, multi-lingual, affordable screening tool that uses voice and facial emotion recognition to identify risks early, from the comfort of home.
Connect by Gabify – a SaaS platform for therapists, schools, and hospitals that streamlines therapy documentation, progress tracking, and parent engagement, cutting admin work by 60%.
Recognized by UNDP, TiE, and SISF, and tested with multiple schools and daycare centers, Gabify is on track to impact 1 million children by 2028.
Our vision is to combine clinical intelligence with emotional intelligence, making early intervention affordable, accessible, and inclusive — turning science into soul, and silence into stories.
Product Screenshots
Business Model
Gabify follows a hybrid B2C and B2B SaaS model, ensuring both affordability for families and scalability for professionals.
Revenue Streams:
AI Screenings (B2C): Parents pay a nominal fee for quick, AI-driven screenings (Autism, ADHD, Dyslexia, speech disorders). These generate developmental reports benchmarked to DSM-5 and CARS.
Therapist SaaS Subscriptions (B2B): Clinics, hospitals, schools, and therapy centers subscribe to Connect by Gabify to automate documentation, track progress, and manage clients. This reduces admin work by 60% and creates recurring SaaS revenue.
Therapy & Consultation Commissions: Gabify earns a small commission on therapy sessions and consultations booked through its verified professional network.
Institutional & CSR Partnerships: Bulk licensing for NGOs, corporates, and government programs enables large-scale screenings for underserved populations.
Future Expansion: Premium features such as predictive analytics, longitudinal data insights, and multilingual upgrades will provide additional monetization opportunities.
This model combines one-time screening fees, recurring SaaS subscriptions, and transaction-based commissions, creating predictable and scalable growth. Our approach aligns financial sustainability with impact, putting Gabify on track to reach 1M+ children by 2028 while building a globally scalable healthtech platform.
Customers
based in
Southeast Asia, South Asia, India, Middle East & North Africa, Australia & New Zealand (Oceania), Africa (excluding North Africa)
Business
Modal Type
SaaS
Type of
Sales
B2B, B2C, B2B2C
Competitors
Gabify operates in the global AI-driven neurodevelopmental and speech therapy space, where several players address parts of the problem but none provide a unified, end-to-end solution.
Major Competitors:
Cognoa (USA): Specializes in AI-based Autism diagnosis tools; strong clinical validation but limited to a single disorder.
Neurotrack (USA): Focuses on cognitive health and memory screening; does not address pediatric speech and neurodevelopmental needs.
Presence (USA): Offers online therapy services, primarily in the U.S., but lacks AI-powered early detection.
Expressable (USA): A teletherapy platform for speech therapy; effective in delivery but without diagnostic AI or multi-disorder coverage.
Local Therapy Apps/Clinics (India): Various small-scale therapy service providers exist, but most lack scalable technology, AI integration, or vernacular support for rural populations.
Gabify’s Differentiation:
Multi-Disorder Coverage (Autism, ADHD, Dyslexia, speech & neuro disorders) vs. competitors’ single-condition focus.
Dual AI Engine (voice + facial emotion recognition) for higher accuracy.
End-to-End Ecosystem (screening + SaaS therapy platform + home/community support) in one solution.
Affordability & Inclusion: Multi-lingual, rural-friendly, low-bandwidth access at a fraction of traditional costs.
Capital Efficiency: Global-level innovation built with far lower funding than competitors, enabling lean and scalable growth.
Teams
Sahil Chopra
Founder & CEO
Prachi Sood
Founder & Chief Speech Therapist
Vasyl Leshchuk
Founder & CTO
Tell us a bit about how founding team knows
each other.
Prachi Sood and Sahil Chopra, partners in life and vision, have known each other for five years. Their travels across multiple countries led them to an inspiring meeting with Vasyl Leshchuk at the British International School in Ukraine. A shared passion for revolutionizing speech and neurological disorder solutions brought them together, forging a powerful alliance that drives Gabify’s mission to create accessible, AI-driven therapy for all.
Why did you decide to start this
company?
We started Gabify to bridge the gap in speech and neuro care, inspired by personal loss, loved ones’ struggles, and a mission to make therapy accessible, affordable, and life-changing for all.
Are all the founders full-time on this
project?
Yes
Looking for an
opportunity to invest in companies
like Gabify?
